Study explores expanding CAR-T therapy for adult acute lymphocytic leukemia patients after initial chemotherapy failure.

A new study at the University of Colorado's Gates Institute examines whether more patients with blood cancer could benefit from chimeric antigen receptor T cell (CAR-T) therapy, a form of immunotherapy using reprogrammed cells from the patient's body to attack cancer cells. The study focuses on adult patients with acute lymphocytic leukemia whose initial chemotherapy has failed or shown limited effectiveness.